Jared Holz, Mizuho, joins ‘Fast Money’ to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
05:29
Fri, Nov 14 20255:58 PM EST
Trending
- Novo Nordisk’s strategy tested as investors push back on board revamp
- Investor Ron Baron says tech selloff an opportunity, won’t sell own Tesla stake
- The AI trade is getting a big repricing. This options trade captures a bounce while mitigating risk
- Shift in the consumer is still in Walmart’s favor, says Telsey’s Joe Feldman
- Walmart Doug McMillon stock performance vs. Target, Amazon, Costco
- Scotland to launch government ‘kilt’ bonds
- D.R. Horton taps Prophetic AI to build more homes
- Merck to acquire Cidara Therapeutics
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho’s Jared Holz
